BCDA vs. LTRN, TPST, PASG, ATNM, ANEB, CALC, SNYR, RLYB, BRNS, and QTTB
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Lantern Pharma (LTRN), Tempest Therapeutics (TPST), Passage Bio (PASG), Actinium Pharmaceuticals (ATNM), Anebulo Pharmaceuticals (ANEB), CalciMedica (CALC), Synergy CHC Corp. (Uplisting) (SNYR), Rallybio (RLYB), Barinthus Biotherapeutics (BRNS), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry.
BioCardia vs.
BioCardia (NASDAQ:BCDA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
Lantern Pharma has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Lantern Pharma's return on equity.
20.6% of BioCardia shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 20.0% of BioCardia shares are owned by insiders. Comparatively, 7.3% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
BioCardia has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lantern Pharma had 1 more articles in the media than BioCardia. MarketBeat recorded 1 mentions for Lantern Pharma and 0 mentions for BioCardia. BioCardia's average media sentiment score of 1.00 beat Lantern Pharma's score of 0.48 indicating that BioCardia is being referred to more favorably in the media.
BioCardia received 4 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 59.26% of users gave BioCardia an outperform vote.
BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 1,046.79%. Given BioCardia's stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than Lantern Pharma.
BioCardia has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.
Summary
BioCardia beats Lantern Pharma on 10 of the 17 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
This page (NASDAQ:BCDA) was last updated on 1/21/2025 by MarketBeat.com Staff
